This study is to see if talampanel helps and is safe to use on adults with partial seizures.

Condition	Treatment or Intervention
Epilepsy	Drug: Talampanel

Ages Eligible for Study:  18 Years   -   65 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• must weigh greater than or equal to 40kg
• Patients must have diagnosis of partial seizures
• At least 3 observable partial seizures a month
• Are currently being treated with 1 and no more than 2 marketed Anti-epileptic Drugs.

Exclusion:

• Patients on Valproic acid, and Felbamate

Cynthia Bell, Ph.D.      305-575-6212    cynthia_bell@ivax.com

Alabama
      UAB Medical Center, Birmingham,  Alabama,  35294,  United States; Recruiting
Arkansas
      Clinical Trials Inc., Little Rock,  Arkansas,  72205,  United States; Recruiting
California
      Stanford University, Stanford,  California,  94305,  United States; Recruiting
Connecticut
      Yale University School of Medicine, New Haven,  Connecticut,  06520,  United States; Recruiting
Florida
      AMO Research, Tallahassee,  Florida,  32308,  United States; Recruiting
      Shands Hospital Jacksonville, Jacksonville,  Florida,  32209,  United States; Recruiting
      University of Miami School of Medicine, Miami,  Florida,  33136,  United States; Recruiting
      Tampa Research Group, Tampa,  Florida,  33613,  United States; Recruiting
      DVAM/Neurology (127), Gainesville,  Florida,  32608,  United States; Recruiting
Illinois
      Southern Illinois University School of Medicine, Springfield,  Illinois,  62702,  United States; Recruiting
Massachusetts
      Beth Israel Deaconess Medical CTR, Boston,  Massachusetts,  02215,  United States; Recruiting
Michigan
      University of Michigan Medical Center, Ann Arbor,  Michigan,  48109,  United States; Recruiting
Missouri
      Comprehensive Epilepsy Care Ctr, Chesterfield,  Missouri,  63017,  United States; Recruiting
      St. John's Medical Research, Springfield,  Missouri,  65804,  United States; Recruiting
New Jersey
      New Jersey Comprehensive Epilepsy Ctr, New Brunswick,  New Jersey,  08901,  United States; Recruiting
New York
      Weill Medical College of Cornell University, New York,  New York,  10021,  United States; Recruiting
Ohio
      University Neurology, Inc, Cincinnati,  Ohio,  45267,  United States; Recruiting
Pennsylvania
      Hospital of the University of Pennsylvania, Philadelphia,  Pennsylvania,  19104,  United States; Recruiting
South Carolina
      Orangeburg Medical Hospital, Orangeburg,  South Carolina,  29118,  United States; Recruiting
Texas
      Baylor Medical Center At Irving, Irving,  Texas,  75061,  United States; Recruiting
Virginia
      University of Virginia Comprehensive Epilepsy Program, Charlottesville,  Virginia,  22908,  United States; Recruiting
Wisconsin
      University of Wisconsin, Madison,  Wisconsin,  53705,  United States; Recruiting
      Marshfield Clinic, Marshfield,  Wisconsin,  54449-5790,  United States; Recruiting

Study ID Numbers:  IXL-201-14-189
Record last reviewed:  July 2004
Record first received:  May 2, 2002
ClinicalTrials.gov Identifier:  NCT00034814
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10